Daily Courier: Single Column

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

143.77 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Feb 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,564
Open 143.77
Bid (Size) 143.00 (100)
Ask (Size) 144.15 (100)
Prev. Close 143.77
Today's Range 143.77 - 143.77
52wk Range 93.37 - 157.29
Shares Outstanding 1,253,809,440
Dividend Yield 2.20%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Kymera (KYMR) Q4 2025 Earnings Call Transcript ↗
Kymera (KYMR) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Merck's Two-Drug HIV Regimen Challenges Industry Standards Following Positive Phase 3 Results
Merck & Co., Inc. (NYSE: MRK) has reached a pivotal milestone in the HIV treatment landscape, announcing successful Phase 3 results for its once-daily oral regimen combining doravirine and islatravir... 
Via MarketMinute
Topics Intellectual Property

Performance

YTD
+18.2%
+18.2%
1 Month
+2.0%
+2.0%
3 Month
+14.2%
+14.2%
6 Month
+27.7%
+27.7%
1 Year
+30.2%
+30.2%

More News

Read More
News headline image
Arcus (RCUS) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
Gilead Sciences Inc (NASDAQ:GILD) Offers a Sustainable Dividend Backed by Strong Fundamentals ↗
Via Chartmill
News headline image
Gilead’s Twice-Yearly HIV Breakthrough: A Paradigm Shift in Global Prevention and Market Dominance
Via MarketMinute
Topics Intellectual Property
News headline image
Eli Lilly Bolsters Genetic Medicine Portfolio with $2.4 Billion Acquisition of Orna Therapeutics
Via MarketMinute
Topics Intellectual Property
News headline image
Gilead’s Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Snaps Up Arcellx For $115 Per Share — A $7.8 Billion Bet On Cancer Therapy ↗
Via Benzinga
News headline image
Is Amgen Stock Outperforming the Dow?
Via Barchart.com
Topics Stocks
News headline image
2 Nasdaq 100 Stocks Worth Your Attention and 1 We Question
Via StockStory
News headline image
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Bets Big On Anito-Cel With $7.8 Billion Arcellx Deal ↗
Via Investor's Business Daily
News headline image
Gilead Buys Arcellx To Fast-Track Next-Gen Myeloma Drug ↗
Via Benzinga
News headline image
Why Did ACLX Stock Surge 80% In Pre-Market Today? ↗
Via Stocktwits
News headline image
Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-cel
From Arcellx, Inc.
Via Business Wire
News headline image
Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million ↗
Via The Motley Fool
News headline image
Where Gilead Sciences Stands With Analysts ↗
Via Benzinga
News headline image
Peering Into Gilead Sciences Inc's Recent Short Interest ↗
Via Benzinga
News headline image
Gilead to Present New HIV Treatment and Prevention Data at CROI 2026, With a Focus on Expanding Options
From Gilead Sciences, Inc.
Via Business Wire
News headline image
5 Insightful Analyst Questions From Gilead Sciences’s Q4 Earnings Call
Via StockStory
Topics Earnings
News headline image
3 Hyped Up Stocks We Steer Clear Of
Via StockStory
News headline image
Cencora, Azenta, The Pennant Group, LifeStance Health Group, and Gilead Sciences Shares Are Soaring, What You Need To Know
Via StockStory
Topics Economy
News headline image
Gilead Sciences and the 2026 Biotech Resurgence: A Leader in the Great Rotation
Via MarketMinute
Topics Artificial Intelligence ETFs Government
News headline image
3 Overrated Stocks That Concern Us
Via StockStory
Exploring the top movers within the S&P500 index during today's session. ↗
Via Chartmill

Frequently Asked Questions

Is Gilead Sciences publicly traded?
Yes, Gilead Sciences is publicly traded.
What exchange does Gilead Sciences trade on?
Gilead Sciences trades on the Nasdaq Stock Market
What is the ticker symbol for Gilead Sciences?
The ticker symbol for Gilead Sciences is GILD on the Nasdaq Stock Market
What is the current price of Gilead Sciences?
The current price of Gilead Sciences is 143.77
When was Gilead Sciences last traded?
The last trade of Gilead Sciences was at 02/26/26 04:00 PM ET
What is the market capitalization of Gilead Sciences?
The market capitalization of Gilead Sciences is 180.26B
How many shares of Gilead Sciences are outstanding?
Gilead Sciences has 180B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

© Copyright 2015, Daily Courier, Kelowna, BC. Powered by BLOX Content Management System from TownNews.com.